Drugs Targeting ALK

  • Alecensa (alectinib) – approved for stage 4 NSCLC patients with a change in ALK as detected by a biomarker test.
  • Alunbrig (brigatinib) – approved for stage 4 NSCLC patients with a change in ALK as detected by a biomarker test who have progressed on another ALK targeted therapy.
  • Lobrena (lorlatinib) – approved for stage 4 NSCLC patients with a change in ALK as detected by a biomarker test and who have progressed on at least two other ALK targeted therapies.
  • Xalkori (crizotinib) – approved for stage 4 NSCLC patients with a change in ALK as detected by a biomarker test.
  • Zykadia (ceritinib) – approved for stage 4 NSCLC patients with a change in ALK as detected by a biomarker test.